Skip to main content
Equibles
CODX logo

CODX · Co-Diagnostics, Inc. · Metrics

Track CODX — free

Use CODX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CODX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.07 +0.00 (+0.00%) At close · Sep 30
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because certain elements of management's plans to mitigate the conditions that raised substantial doubt about the Company's ability to continue as a going concern are outside of the Company's control, including the ability to raise capital through equity or other financings, those elements cannot be considered probable according to ASC 205-40, and therefore cannot be considered in the evaluation of mitigating factors. As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$6.82M
Shares
6.25M
Volume · Sep 30 87.38K Avg daily vol (3M) 425.08K

CODX metrics

60 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.07
Market cap
$6.82M

Price action

20 metrics
Price change (1W)
-0.9%
Price change (30D)
-13.7%
Price change (3M)
-65.5%
Price change (6M)
-42.5%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
243.2%
Annualized volatility (3M)
91.2%
Beta
1.1
RSI (14D)
40.5
Price vs SMA 50
-20.1%
Price vs SMA 200
—
Avg volume (3M)
426,179
Relative volume
0.2
Average dollar volume
$813,607

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
6.25M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
9.4×
reciprocal yield 10.6%
P / book
0.5
reciprocal yield 186.5%
FCF yield
-403.1%
TTM · current market cap
Buyback yield
20.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-690.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
20.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
43.5%
Operating margin
-6,787.6%
Trailing 12 months
Net margin
-6,523.0%
Gross profit (TTM)
$313,635
Operating profit (TTM)
−$48.96M
Net income (TTM)
−$47.06M
Trailing 12 months
Diluted EPS (TTM)
$-26.72
FCF margin
-3,808.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$295.39

Growth

11 metrics
Revenue growth YoY
+2.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$721,387
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+290.5%
Year over year · more shares
Revenue CAGR (3Y)
-73.7%
Revenue CAGR (5Y)
-61.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-370.2%
Return on assets
-283.6%
Debt / equity
—
Current ratio
1.8
EBITDA (TTM)
−$47.97M
Free cash flow (TTM)
−$27.47M
Quick ratio
1.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.65M
Total assets
$16.59M
Total debt
$3.82M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$27.10M
Capital expenditures (TTM)
$367,372
R&D (TTM)
$19.67M
SG&A (TTM)
—
Stock compensation (TTM)
$1.23M
R&D / revenue
2,726.2%
Stock compensation / revenue
169.9%

Ownership (13F)

3 metrics
13F filers
24
13F filer change QoQ
+10
Institutional ownership
9.5%

Short interest

3 metrics
Short interest
4.9%
Latest settlement · 2.4 days to cover
Days to cover
2.4d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1692415 CUSIP 189763204 13F (30d) 1 filings 1 filers Visit website Investor relations